Hairy cell leukemia (HCL) is an unusual cancer of the blood. It affects B cells, a type of white blood cell (lymphocyte).
HCL is caused by the abnormal growth of B cells. The cells look "hairy" under the microscope because they have fine projections extending from their surface.
HCL usually leads to a low number of normal blood cells.
The cause of this disease is unknown. Certain genetic changes (mutations) in the cancer cells may be the cause. It affects men more often than women. The average age of diagnosis is 55.
Exams and Tests
Blood tests that may be done include:
Treatment may not be needed for the early stages of this disease. Some people may need an occasional blood transfusion.
If treatment is needed because of very low blood counts, chemotherapy drugs can be used.
In most cases, chemotherapy can relieve the symptoms for many years. When the signs and symptoms go away, you are said to be in remission.
Removing the spleen may improve blood counts, but is unlikely to cure the disease. Antibiotics can be used to treat infections. People with low blood counts may receive growth factors and, possibly, transfusions.
Most people with HCL can expect to live 10 years or longer after diagnosis and treatment.
The low blood counts caused by hairy cell leukemia can lead to:
- Excessive bleeding
There is no known way to prevent this disease.
Leukemic reticuloendotheliosis; HCL; Leukemia - hairy cell
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): hairy cell leukemia. Updated May 3, 2016. Version 3. 2016. www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed July 11, 2016.
Park JH, Tallman MS. Hairy cell leukemia. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2014:chap 103.
Ravandi F. Hairy cell leukemia. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013:chap 77.
Review Date 5/20/2016
Updated by: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.